Impact of the Glucagon Assay When Assessing the Effect of Chronic Liraglutide Therapy on Glucagon Secretion | Zendy

Caroline K. Kramer | Zendy; Bernard Zinman | Zendy; Haysook Choi | Zendy; Philip W. Connelly | Zendy; Ravi Retnakaran | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact of the Glucagon Assay When Assessing the Effect of Chronic Liraglutide Therapy on Glucagon Secretion

Author(s) -

Caroline K. Kramer,

Bernard Zinman,

Haysook Choi,

Philip W. Connelly,

Ravi Retnakaran

Publication year - 2017

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2017-00928

Subject(s) - liraglutide , glucagon , placebo , medicine , endocrinology , diabetes mellitus , glucagon like peptide 1 , area under the curve , type 2 diabetes , insulin , alternative medicine , pathology

Glucagon-like peptide-1 agonists acutely lower serum glucagon. However, in the Liraglutide and β-Cell Repair (LIBRA) Trial, 48-week treatment with liraglutide yielded lower/unchanged fasting glucagon but, surprisingly, enhanced postchallenge glucagonemia [measured by R&D Systems (Minneapolis, MN) assay].

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research